Artiva Biotherapeutics halts AlloNK development, cuts staff by 94%Oct 27Quarterly updateArtiva Biotherapeutics, Inc.Biogen
AbbVie posts TEMPLE Phase 3 results for atogepant vs topiramate; opens three early-stage trialsJul 2Weekly roundup, 5 itemsABBV-313AbbVie